Quentin Moyon

Quentin Moyon

Auto-generated profile, based on publicly available information

Quentin Moyon

INSERM, UMRS 1166-ICAN, Institute of Cardiometabolism and Nutrition, Sorbonne University, Paris, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2021 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
QMQuentin Moyon
Quentin Moyon
GLGuillaume Lebreton
Guillaume Lebreton
FHFlorent Huang
Florent Huang
PDPierre Demondion
Pierre Demondion
CDCyrielle Desnos
Cyrielle Desnos
MCMarc Pineton de Chambrun
Marc Pineton de Chambrun
OBJECTIVES: Postoperative mediastinitis, a feared complication after cardiac surgery, is associated with high mortality, especially of critically ill patients. Candida species infections are rare and severe, with poorly known outcomes. We conducted a case–control study to describe the characteristics, management and outcomes of patients with postoperative Candida mediastinitis. METHODS: This French, monocentre, retrospective study included all patients with postoperative Candida mediastinitis (January 2003–February 2020) requiring intensive care unit admission. Candida mediastinitis patients (henceforth cases) were matched 1:1 with postoperative bacterial mediastinitis (henceforth control), based on 3 factors during mediastinitis management: age >40 years, cardiac transplantation and invasive circulatory device used. The primary end point was the probability of survival within 1 year after intensive care unit (ICU) admission. RESULTS: Forty cases were matched to 40 controls. The global male/female ratio was 2.1, with mean age at admission 47.9 ± 13.8 years. Candida species were: 67.5% albicans, 17.5% glabrata, 15% parapsilosis, 5.0% tropicalis, 2.5% krusei and 2.5% lusitaniae. The median duration of mechanical ventilation was 23, 68.8% of patients received renal replacement therapy and 62.5% extracorporeal membrane oxygenation support. The probability of survival within the first year after ICU admission was 40 ± 5.5% and was significantly lower for cases than for controls (43 ± 8% vs 80 ± 6.3%, respectively; Log-rank test: P < 0.0001). The multivariable Cox proportional hazards model retained only renal replacement therapy [hazard ratio (HR) 3.7, 95% confidence interval (CI) 1.1–13.1; P = 0.04] and Candida mediastinitis (HR 2.4, 95% CI 1.1–5.6; P = 0.04) as independently associated with 1-year mortality. CONCLUSIONS: Candida mediastinitis is a serious event after cardiac surgery and independently associated with 1-year mortality. Further studies are needed to determine whether deaths are directly attributable to Candida mediastinitis.

17 September 2023 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
CMClémence Marin
Clémence Marin
GNGaelle Noé
Gaelle Noé
DSDimitri Schlemmer
Dimitri Schlemmer
QBQuentin Beaulieu
Quentin Beaulieu
PRPascal Robidou
Pascal Robidou
NZNoël ZAHR
Noël ZAHR

19 January 2024 in Rheumatology
Verified
Journal Article
Closed access
PDF file
ABArthur Bouchut
Arthur Bouchut
RLRaphael Lhote
Raphael Lhote
PMPhilippe Maksud
Philippe Maksud
TSThouraya Ben Salem
Thouraya Ben Salem
AFAnne Fustier
Anne Fustier
FAFleur Cohen Aubart
Fleur Cohen Aubart
Sarcoidosis is a multisystemic granulomatosis diagnosed mainly in young adults. 18F-fluorodeoxyglucose (18F-FDG) PET/CT is useful in sarcoidosis cases to search for a biopsiable site or assess disease activity.18F-FDG PET/CT can reveal bone hypermetabolism in sarcoidosis patients, even in the absence of osteoarticular symptoms. The aim of this study was to describe metabolic bone involvement in sarcoidosis patients and to evaluate its prognostic impact. This was an observational, comparative, retrospective, monocentric study. Inclusion criteria were a confirmed diagnosis of sarcoidosis according to the World Association of Sarcoidosis and Other Granulomatous Diseases (WASOG) criteria and at least one 18F-FDG PET/CT scan during follow-up. Metabolic bone involvement of sarcoidosis was defined as focal bone hypermetabolism with no argument for a differential diagnosis of bone 18F-FDG uptake. Patients with and without bone involvement were compared. Among the 175 included patients, 32 (18%) had metabolic bone involvement of sarcoidosis. The metabolic bone involvement was mainly axial and mostly without bone abnormalities on CT. Metabolic bone involvement was associated with intrathoracic and extrathoracic lymph node involvement and with a greater number of organs involved. Patients with metabolic bone involvement more frequently received corticosteroids, methotrexate and TNF-α inhibitors and a greater number of treatments. Relapse of sarcoidosis occurred sooner in patients with metabolic bone involvement. These results suggest that metabolic bone involvement is associated with more diffuse and more severe sarcoidosis.

29 June 2026 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
QMQuentin Moyon
Quentin Moyon
GHGreet Hermans
Greet Hermans
DADarryl Abrams
Darryl Abrams
CACara Agerstrand
Cara Agerstrand
MAMichaela R. Anderson
Michaela R. Anderson
DBDaniel Brodie
Daniel Brodie

17 April 2026 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
CHChahem Harba
Chahem Harba
ADAlexis David-Papadopoulos
Alexis David-Papadopoulos
AFAnouk Frering
Anouk Frering
GLGuillaume Lebreton
Guillaume Lebreton
SGSoulef Guendouz
Soulef Guendouz
QMQuentin Moyon
Quentin Moyon

15 June 2022 in La Revue de Médecine Interne
Verified
Journal Article
Closed access
ABA. Bouchut
A. Bouchut
RLR. Lhote
R. Lhote
PMP. Maksud
P. Maksud
TST. Ben Salem
T. Ben Salem
AFA. Fustier
A. Fustier
FAF. Cohen Aubart
F. Cohen Aubart